

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 16596-049US1	Application No. 10/509,194
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)  (37 CFR §1.98(b))		Applicant Alemany Bonastre, Ramon, et al.	
		Filing Date September 23, 2004	Group Art Unit <del>Unknown</del> 1633

U.S. Patent Documents							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
SP	AA	5002874	03/1991	Kaufman			

Foreign Patent Documents or Published Foreign Patent Applications								
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
SP	AB	98/35028	08/1998	WO				
SP	AC	01/35970	05/2001	WO				

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
SP	AD	Alemany et al., "Replicative adenoviruses for cancer therapy", <i>Nature Biotechnology</i> 18, 723-727, 2000
	AE	Bergmann et al., "A genetically Engineered Influenza A Virus with <i>ras</i> -Dependent Oncolytic Properties", <i>Cancer Research</i> , 61: 8188-8193, 2001
	AF	Fowlkes et al., "Transcriptional Control Regions of the Adenovirus VAI RNA Gene" <i>Cell</i> 22, 405-413, 1980
	AG	Fueyo et al., "A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect <i>in vivo</i> ", <i>Oncogene</i> 19, 2-12, 2000
	AH	Gunnery et al. "Termination Sequence Requirements Vary among Genes Transcribed by RNA polymerase III" <i>Journal of Molecular Biology</i> 286 745-757, 1999
	AI	Ma et al. "Structure, Function, and Evolution of Adenovirus-Associated RNA: a Phylogenetic Approach", <i>Journal of Virology</i> 70(8), 5083-5099, 1996
	AJ	Mundschaue et al., "Oncogenic <i>ras</i> Induces an Inhibitor of Double-stranded RNA-dependent Eukaryotic Initiation Factor 2 $\alpha$ -kinase Activation", <i>Journal of Biological Chemistry</i> , 267(32): 23092-23098, 1992
	AK	Norman et al., "Reovirus as a novel oncolytic agent", <i>Journal of Clinical Investigation</i> 105: 1035-1038, 2000
↓	AL	Stojdl et al., "Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus", <i>Nature Medicine</i> 6(7): 821-825, 2000

Examiner Signature /Scott Priebe/	Date Considered 12/12/2006
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	